Mirtazapine and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is found among people who take Mirtazapine, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Mirtazapine and have Poor venous access. It is created by eHealthMe based on reports of 65,788 people who have side effects when taking Mirtazapine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

65,788 people reported to have side effects when taking Mirtazapine.
Among them, 48 people (0.07%) have Poor venous access.


What is Mirtazapine?

Mirtazapine has active ingredients of mirtazapine. It is often used in depression. eHealthMe is studying from 61,153 Mirtazapine users for its effectiveness, alternative drugs and more.

What is Poor venous access?

Poor venous access is found to be associated with 680 drugs and 345 conditions by eHealthMe.

Number of Mirtazapine and Poor venous access reports submitted per year:

Could Mirtazapine cause Poor venous access?

Gender of people who have Poor venous access when taking Mirtazapine *:

  • female: 76.47 %
  • male: 23.53 %

Age of people who have Poor venous access when taking Mirtazapine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 16.67 %
  • 20-29: 3.33 %
  • 30-39: 3.33 %
  • 40-49: 3.33 %
  • 50-59: 30.0 %
  • 60+: 43.33 %

Common drugs people take besides Mirtazapine *:

  1. Ativan: 13 people, 27.08%
  2. Inflectra: 12 people, 25.00%
  3. Calcium: 12 people, 25.00%
  4. Solu-Medrol: 11 people, 22.92%
  5. Benadryl: 10 people, 20.83%
  6. Morphine: 10 people, 20.83%
  7. Plaquenil: 9 people, 18.75%
  8. Pantoprazole: 9 people, 18.75%
  9. Tylenol: 8 people, 16.67%
  10. Spiriva: 8 people, 16.67%

Common side effects people have besides Poor venous access *:

  1. High Blood Pressure: 23 people, 47.92%
  2. Weight Increased: 21 people, 43.75%
  3. Nausea (feeling of having an urge to vomit): 20 people, 41.67%
  4. Weight Decreased: 16 people, 33.33%
  5. Hypotension (abnormally low blood pressure): 13 people, 27.08%
  6. Sepsis (a severe blood infection that can lead to organ failure and death): 13 people, 27.08%
  7. Infusion Related Reaction: 12 people, 25.00%
  8. Cough: 11 people, 22.92%
  9. Fatigue (feeling of tiredness): 11 people, 22.92%
  10. Productive Cough: 10 people, 20.83%

Common conditions people have *:

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 21 people, 43.75%
  2. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 16.67%
  3. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 6 people, 12.50%
  4. Migraine (headache): 5 people, 10.42%
  5. Vasculitis (inflammation of a blood vessel or blood vessels): 4 people, 8.33%
  6. Immunodeficiency Common Variable: 3 people, 6.25%
  7. Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 4.17%
  8. Rashes (redness): 1 person, 2.08%
  9. Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 2.08%
  10. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.08%

* Approximation only. Some reports may have incomplete information.

Do you take Mirtazapine and have Poor venous access?

Check whether Poor venous access is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Poor venous access and when was it recovered:

Expand to all the drugs that have ingredients of mirtazapine:

Alternative drugs to, pros and cons of Mirtazapine:

Common Mirtazapine side effects:

Browse all side effects of Mirtazapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Poor venous access treatments and more:

COVID vaccines that are related to Poor venous access:

Common drugs associated with Poor venous access:

All the drugs that are associated with Poor venous access:

Common conditions associated with Poor venous access:

All the conditions that are associated with Poor venous access:

How the study uses the data?

The study uses data from the FDA. It is based on mirtazapine (the active ingredients of Mirtazapine) and Mirtazapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: